Welcome as a shareholder in Nordiq Products AS

Your investment can save lives, and we look forward to having you help revolutionize patient monitoring in demanding environments.

Contact us if you have any questions or would like to discuss investment opportunities in more detail.

We are committed to keeping our shareholders informed and engaged.
As a shareholder, you will receive regular updates via email with insights into the company's development, milestones and strategic progress.
Also follow us on LinkedIn for regular updates: Nordiq@LinkedIn
Thank you for wanting to be part of Nordiq Products' growth and future!

Vegard Midjo - Chief Business Officer

Phone: +47 996 17 985
Email: vegard@nordiqproducts.com


Mats Hetling - Chief Executive Officer

Phone: +47 928 08 095
Email: mats@nordiqproducts.com

Nordiq revolutionizes field medicine with LiSa™

The world's first portable patient monitor that measures the most important vital signs, including respiration in real time, with a display and easy mounting on the neck.

Nordiq Products develops LiSa™, an ultra-portable, robust and reliable vital signs monitor, designed for use in demanding situations by military medics, rescue teams and other first responders.

LiSa™ is made possible through unique, proprietary sensor technology , based on the expertise of Professor Lise Lyngsnes Randeberg, PhD in biomedical optics and SINTEF's cutting-edge expertise in acoustics.

LiSa™ continuously monitors pulse, oxygen saturation and respiratory rate, and alerts when life-threatening changes occur – a feature not currently available in any wearable device. The technology gives paramedics a critical advantage in the field, replacing unreliable methods such as manual observation and fingertip measurement.

Intro film about LiSa™

Here's how to proceed with investing:

1. Register your interest

You can express your interest in investing in Nordiq Products via the “Register Interest” form. The indicative investment amount is non-binding.
Note: minimum investment requirement is NOK 42,170 (10 shares).

3. Make your investment

Do you think the investment sounds interesting? Place an order for shares in Orgbrain.no and the company will contact you with a subscription form and payment information.

2. Get access to information and the ability to order shares

Once you have registered your interest, the company will provide you with personal follow-up and you can get answers to any questions you may have. If you are ready to invest, you will receive a personal invitation to Orgbrain.no where you can order shares.

LiSa™ is made for :
Military, SAR, Police, Fire and Rescue, First Responders, and Emergency Medical Personnel.

Here are some statements about LiSa™ from potential customers and users

  • "The use of this device will significantly accelerate the preliminary diagnosis process. This, in turn, will greatly enhance the survival rates of the wounded by providing faster and more comprehensive information within a short period.”

    - Yulia Paevska, famous Ukrainian military medic.

  • “I work as a dog handler for the department. What you are developing could open up a whole new world for treating casualties.”

    Dog handler in the Armed Forces and former head of sanitation for the department.

  • “I was told that you have an incredibly exciting solution for patient monitoring that could be a hit with those of us who operate in harsh weather conditions.”

    - Section manager, specialist in first aid and emergency medicine.

  • “This is definitely something that is of interest. Being able to free up capacity by having such a monitoring option is the alpha and omega for retrieval missions with, for example, ATVs, or finding people out in the field who need to be monitored. It ensures that the data we measure (which is currently done manually) is correct. We can easily imagine that this is a product we want to buy.”

    - Chairman of the local Red Cross branch

We have collected some quotes from potential users of LiSa™ that demonstrate its potential in the market:

Details about your investment

The purpose of the issue is to strengthen the company's capital base to carry out necessary development activities.

The minimum investment requirement is set at NOK 42,170 (10 shares).

The subscription price is now set at 4,217 ,- NOK per share, which implies a company value of 37,473,908 ,- NOK before the issue.

The issue will, among other things, finance Prototyp v4 and bring us closer to “design freeze”.

Prototype v4 is a critical milestone that will give us a technological boost and strengthen our commercial position with potential customers, partners and investors. It also represents a necessary step before we move forward with regulatory approvals.
With 3 million NOK we will complete Prototype 4 within about 3 months.

Triggers government support

Almost all of our capital goes to R&D in the company, and of this the state covers 67% in our case. This means that if we spend 1 million on R&D, we only use 330,000kr of the added capital. This means that you trigger a great value for the company with an investment, and that your investment thus has a good starting point for a good return.

New support opportunities

Added capital will also trigger the possibility of an Innovation Contract with Innovation Norway, where the plan has already been prepared over time in dialogue with IN, but where we lack the necessary capital for approval of the project.

“Return on Investment”

Similar companies that achieve success have shown returns on investments made in a similar phase of up to 12x of the invested amount, if the company is sold in a later growth phase after launching in the market. Our goal is to reach this phase within 5 years.

Nordiq's Strengths

✔ Unique Technology – First wearable device to monitor respiration in real time, using proprietary optical and acoustic sensor technology.

✔ Tested with the military – Nordiq has participated in the Arctic Warrior Experiment (TE25-1) with USSOCOM, NORSOCOM and FFI, confirming LiSa™'s strategic value to the defense sector.

✔ Strong IP protection – Patent granted in the UK, and patent applications pending in multiple markets.

✔ Attractive market – Large needs in defense, rescue and emergency medicine, with high willingness to pay for better patient monitoring and preparedness.

✔ Scalable business model – International sales to defense, ambulances, rescue services and B2B partnerships with medtech suppliers.

Here you can see our pitch deck for a short presentation of the project:
pitchdeck.nordiqproducts.com